FDA to review rheumatoid arthritis drug for pediatric use

Article

Bristol-Myers Squibb (BMS) said the FDA has agreed to review the company’s supplemental biologics license application for its arthritis drug, abatacept (Orencia). The drug is currently used by adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response to one or more anti-rheumatic medications. [more]

Bristol-Myers Squibb (BMS) said the FDA has agreed to review the company’s supplemental biologics license application for its arthritis drug, abatacept (Orencia). The drug is currently used by adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response to one or more anti-rheumatic medications. [more]

BMS is requesting that abatacept be approved for pediatric patients with juvenile idiopathic arthritis who have had an inadequate response to one or more anti-rheumatic drugs. In support of its application, the company is using data from a double-blind, randomized clinical trial with participants who range in age from 6 to 17 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.